Influence of GO-Antisense miRNA-21 on the Expression of Selected Cytokines at Glioblastoma Cell Lines.
cancer
glioblastoma
graphene oxide
miRNA delivery
miRNA-21
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
05
2023
accepted:
24
07
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Graphene oxide (GO) is a single layer of carbon atoms with unique properties, which are beneficial due to its surface functionalisation by miRNA. miRNAs are a non-coding small form of RNA that suppress the expression of protein-coding genes by translational repression or degradation of messenger RNA. Antisense miRNA-21 is very promising for future investigation in cancer therapy. This study aimed to detect cytokine expression levels after the administration of GO-antisense miRNA-21 into U87, U118, U251 and T98 glioma cell lines. U87, U118, U251 and T98 glioma cell line were investigated in term of viability, human cytokine expression level at protein and genes after treatment with GO, GO-antisense miRNA-21 and antisense miRNA-21. The delivery of antisense miRNA-21 into the glioma cell at in vitro investigation were conducted by GO based transfection and electroporation. The results of the protein microarray and gene expression profile showed that complexes of GO-antisense miRNA-21 modified the metallopeptidase inhibitor 2 (TIMP-2), interleukin-6 (IL-6), interleukin 8 (IL-8), intercellular adhesion molecule 1 (ICAM-1), and monocyte chemoattractant protein-1 (MCP-1) expression level compared to transfection by electroporation of antisense miRNA-21 at investigated glioblastoma cell lines. The TIMP-2 protein and gene expression level was upregulated after antisense miRNA-21 delivery by GO complex into U87, U251 and T98 glioblastoma cell lines comparing to the non-treated control group. The downregulation at protein expression level of ICAM - 1 was observed at U87, U118, U251 and T98 glioma cell lines. Moreover, the IL-8 expression level at mRNA for genes and protein was decreased significantly after delivery the antisense-miRNA-21 by GO compared to electroporation as a transfection method. This work demonstrated that the graphene oxide complexes with antisense miRNA-21 can effectively modulate the cytokine mRNA and protein expression level at U87, U118, U251 and T98 glioma cell lines.
Identifiants
pubmed: 37662685
doi: 10.2147/IJN.S419957
pii: 419957
pmc: PMC10473248
doi:
Substances chimiques
Cytokines
0
Interleukin-8
0
graphene oxide
0
Tissue Inhibitor of Metalloproteinase-2
127497-59-0
MIRN21 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4839-4855Informations de copyright
© 2023 Kutwin et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
ACS Nano. 2010 Oct 26;4(10):5731-6
pubmed: 20925398
Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):195-215
pubmed: 26502273
Drug Discov Today. 2017 Feb;22(2):424-432
pubmed: 27815139
Mol Med Rep. 2016 Dec;14(6):5363-5368
pubmed: 27840916
J Mater Chem B. 2023 Mar 22;11(12):2568-2613
pubmed: 36883982
Biomaterials. 2016 Apr;86:33-41
pubmed: 26878439
Bioeng Transl Med. 2022 Jun 21;8(1):e10347
pubmed: 36684103
MRS Commun. 2018 Sep;8(3):642-651
pubmed: 30705781
ACS Omega. 2020 Jan 15;5(3):1656-1668
pubmed: 32010840
Oncogene. 2013 Oct 24;32(43):5144-55
pubmed: 23178493
Adv Immunol. 1995;58:417-54
pubmed: 7741031
Int J Nanomedicine. 2014 May 15;9:2409-17
pubmed: 24876774
Biomaterials. 2012 Nov;33(32):8017-25
pubmed: 22863381
J Biol Chem. 1990 Aug 15;265(23):13933-8
pubmed: 2380196
Oncotarget. 2017 Jun 29;8(57):96970-96983
pubmed: 29228586
Nanoscale Res Lett. 2015 Dec;10(1):398
pubmed: 26459428
Front Oncol. 2022 Jan 25;11:720622
pubmed: 35145899
Clin Cancer Res. 2005 May 15;11(10):3624-32
pubmed: 15897557
Sci Rep. 2018 Oct 3;8(1):14733
pubmed: 30283098
Environ Int. 2021 Jul;152:106497
pubmed: 33714870
Molecules. 2021 Sep 25;26(19):
pubmed: 34641347
Acta Biomater. 2013 Dec;9(12):9243-57
pubmed: 23958782
J Dent Sci. 2020 Mar;15(1):65-74
pubmed: 32257002
Brain Sci. 2022 Apr 15;12(4):
pubmed: 35448036
Neoplasia. 2015 Jun;17(6):481-9
pubmed: 26152356
J Nanobiotechnology. 2015 Oct 30;13:78
pubmed: 26518450
Biomaterials. 2017 Mar;121:144-154
pubmed: 28088076
Annu Rev Pathol. 2009;4:199-227
pubmed: 18817506
Trends Biotechnol. 2011 May;29(5):205-12
pubmed: 21397350
ACS Nano. 2011 May 24;5(5):3693-700
pubmed: 21500856
Lab Invest. 2004 Jan;84(1):8-20
pubmed: 14631378
ACS Appl Mater Interfaces. 2019 Jul 3;11(26):22915-22924
pubmed: 31252460
Toxicol Rep. 2020 Nov 06;7:1514-1530
pubmed: 33251119
ACS Appl Mater Interfaces. 2011 Jul;3(7):2607-15
pubmed: 21650218
Pharmaceuticals (Basel). 2022 Aug 23;15(9):
pubmed: 36145257
Gynecol Oncol. 2016 Mar;140(3):512-7
pubmed: 26768834
Drug Dev Res. 2015 Sep;76(6):270-7
pubmed: 26082192
Cell Death Dis. 2019 Mar 29;10(4):292
pubmed: 30926789
Hum Gene Ther. 2018 Feb;29(2):160-179
pubmed: 29338444